Head to Head Analysis: BridgeBio Oncology Therapeutics (BBOT) vs. Its Rivals

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is one of 318 public companies in the “Investment Offices” industry, but how does it weigh in compared to its peers? We will compare BridgeBio Oncology Therapeutics to related businesses based on the strength of its dividends, profitability, valuation, risk, earnings, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. Comparatively, 48.4% of shares of all “Investment Offices” companies are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by company insiders. Comparatively, 29.1% of shares of all “Investment Offices” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares BridgeBio Oncology Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	-$134.04 million	-4.38
BridgeBio Oncology Therapeutics Competitors	$56.46 million	-$145.21 million	-421.77

BridgeBio Oncology Therapeutics’ peers have higher revenue, but lower earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares BridgeBio Oncology Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	N/A	N/A
BridgeBio Oncology Therapeutics Competitors	697.12%	-3.34%	-1.94%

Volatility and Risk

BridgeBio Oncology Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, BridgeBio Oncology Therapeutics’ peers have a beta of 0.45, indicating that their average stock price is 55% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for BridgeBio Oncology Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1	0	4	0	2.60
BridgeBio Oncology Therapeutics Competitors	320	84	127	2	1.65

BridgeBio Oncology Therapeutics presently has a consensus target price of $25.00, indicating a potential upside of 178.71%. As a group, “Investment Offices” companies have a potential upside of 29.62%. Given BridgeBio Oncology Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than its peers.

Summary

BridgeBio Oncology Therapeutics beats its peers on 8 of the 13 factors compared.

About BridgeBio Oncology Therapeutics

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.